12,707 Shares in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Acquired by Atlas Legacy Advisors LLC

Atlas Legacy Advisors LLC purchased a new position in shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 12,707 shares of the company’s stock, valued at approximately $26,000.

Lixte Biotechnology Trading Down 1.4 %

LIXT opened at $1.41 on Thursday. Lixte Biotechnology Holdings, Inc. has a 12-month low of $1.31 and a 12-month high of $4.40. The firm has a market capitalization of $3.17 million, a PE ratio of -0.82 and a beta of -0.04. The firm has a 50 day moving average of $2.20 and a two-hundred day moving average of $2.00.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.